Progenics falls on deaths in Phase II trial

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) fell $1.70 (27%) to $4.50 on Wednesday after an abstract from the American Society of Clinical Oncology Genitourinary Cancers Symposium noted that two patients receiving IV PSMA ADC died due to sepsis in the Phase II PSMA ADC 2301 trial to treat metastatic castration-resistant prostate cancer (CRPC). The open-label, U.S. trial has enrolled 70 CRPC patients with progressive disease despite treatment with one or more taxane-containing chemotherapies. The trial also has an additional cohort of 35 chemotherapy-naïve patients who have progressed on hormonal therapies. The abstract, which includes safety and efficacy data, is slated to be presented at the symposium on Thursday. ...